Volume 27, Issue 12, December 2022

There is renewed focus on promoting inclusion of patients from racial and ethnic minority groups in oncology clinical trials. This commentary analyzes postmarketing studies racial and ethnic minorities issued by the FDA’s Office of Oncologic Diseases.

Managing bone health after denosumab cessation is a commonly encountered challenge. Although the “rebound phenomenon” is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the evidence on the efficacy and safety of various bone health agents in mitigating the “rebound phenomenon” in cancer populations.

Recurrent head and neck squamous cell carcinoma (HNSCC) remains lethal despite recent advances with immunotherapy, and effective targeted therapies are still needed. This article reports on the efficacy of the PI3K/mTOR inhibitor bimiralisib in patients with NOTCH1-mutant HNSCC.

Given the pervasiveness and lethality of metastatic colorectal cancer (CRC), new therapies are urgently needed. This article explores a novel combination therapy to bypass anti-EGFR resistance if the appropriate patient population is selected.

Pseudocirrhosis is an imaging finding for malignancies with liver metastasis with or without clinical liver cirrhosis-related portal hypertension (pHTN). This study defined evident pHTN by the presence of esophageal or gastric varices and compared patients’ outcomes of metastatic breast cancer with imaging-diagnosed pseudocirrhosis with or without varices. Results are reported here.

Although vaccines against COVID-19 are available to patients with cancer, few data are available on their efficacy in patients undergoing active anti-cancer therapies. This study evaluated the serologic responses from standard doses of COVID-19 vaccines in patients with early breast cancer.

This study assesses genomic differences among a large series of pelvic squamous cell carcinoma (pSCC) cases to determine whether pSCC could potentially benefit from targeted therapies and/or immunotherapy.

This retrospective analysis of patients with metastatic and locally advanced pancreatic ductal adenocarcinoma characterizes prognostic or predictive genomic markers for this patient population, with a focus on KRAS mutational variants and their interaction with concurrent molecular alterations.

The role of perioperative chemotherapy in colorectal cancer liver metastasis is unclear. This review evaluates the efficacy of perioperative systemic therapies for patients with colorectal cancer liver metastasis.

This article reports an open-label, noncomparative cohort of the REACH-2 study, which was initiated to address the data gap that exists on the safety and efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and a baseline AFP ≥400 ng/mL after non-sorafenib-based systemic therapies.

Microphtalmia transcription factor (MiT) family translocation renal cell carcinoma (TRCC) is a rare subtype of renal cell carcinoma.

This article evaluates the efficacy and safety of single-agent sapanisertib, and of sapanisertib plus the PI3Kα inhibitor TAK-117, versus everolimus in patients with advanced clear cell renal cell carcinoma that had progressed on or after VEGF-targeted therapy.

Adherence to prescribed oral anticancer treatments is underestimated and difficult to measure in oncology and can affect treatment efficacy, safety, and costs, especially in frail and older patients. This article evaluates adherence to abiraterone and enzalutamide in an observational cohort study of older patients with metastatic castration-resistant prostate cancer.

This article presents the most recent data regarding 177Lu-PSMA-radioligand therapy for patients with metastatic castration-resistant prostate cancer.

This indirect treatment comparison assessed dostarlimab efficacy and safety compared with doxorubicin in advanced or recurrent endometrial cancer.

This article explores physicians’ perspectives on extrapolating results to patients underrepresented in cancer clinical trials that test less intense treatment for patients, focusing on breast cancer.

This review provides the practicing oncologist with the tools to address end-of-life (EOL) care in the Hispanic/Latinx population. The authors encourage oncologists to discuss EOL care and engage family members while practicing cultural humility.

This article reports on the effects of an open-labeled placebo compared with wait-list control in reducing cancer-related fatigue in patients with advanced cancer using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

This article reports a case of recurrent hypophysitis following immune checkpoint inhibitor rechallenge for metastatic melanoma.

To assess the success rate of comprehensive genomic profiling for patients with prostate cancer, a real-world cohort that underwent sequencing of prostate tissue samples was analyzed, including a subset of patients with a reflex liquid biopsy.

This narrative describes an innovative program using integrative medicine therapies to improve the well-being of patients and providers in a hospital’s COVID-19 departments.

This letter to the editor comments on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.